Category

Archives

RNR

Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production

323 views | Oct 26 2023

In this study, the increased expression of ribonucleotide reductase regulatory subunit M2 (RRM2) and its regulation of dGTP and dCTP production during temozolomide (TMZ) therapy were identified as key factors in driving chemoresistance in glioblastoma (GBM), and treatment with the RRM2 inhibitor 3-AP (Triapine) improved the efficacy of TMZ therapy in patient-derived xenograft (PDX) models. [Read the Full Post]

Purine Antimetabolites associated Pneumocystis Jiroveci Pneumonia

393 views | Oct 20 2023

The retrospective disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database revealed a significant safety signal for pneumocystis jiroveci pneumonia (PJP) associated with purine antimetabolites, particularly fludarabine and thioguanine, among populations with autoimmune disorders and cancer. [Read the Full Post]